You are here

  • Home
  • Archive
  • Volume 73, Issue 1
  • Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

Citation Tools

Article menu
Clinical and epidemiological research
Extended report
Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Wallace DJ, Kalunian K, Petri MA, et al
Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
Annals of the Rheumatic Diseases 2014;73:183-190.